Clinical Edge Journal Scan

PsA: Patients have high anxiety levels that decline after initiation of biologics


 

Key clinical point: Patients with psoriatic arthritis (PsA) have high anxiety levels before initiating biologics, which decreased within 6 months thereafter and was tied with better patient outcomes.

Major finding: Overall, 64% of patients had high anxiety levels before initiating biologics, with the proportion of patients with high anxiety levels and mean anxiety scores decreasing significantly within 6 months of initiating biologics (both P < .001). A change in anxiety score correlated positively with a change in pain score, patient global assessment score, Bath Ankylosing Spondylitis Disease Activity Index, Health Assessment Questionnaire-Disability Index score, Disease Activity Score-28, and PsA Impact of Disease score (all P < .05).

Study details: Findings are from an analysis of 147 patients with PsA who initiated biologic agents and had an anxiety score assessed at both baseline and first visit within 6 months.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Ayan G et al. Clin Rheumatol. 2022 (Jan 27). Doi: 10.1007/s10067-021-06012-y.

Recommended Reading

Guselkumab controls axial involvement in PsA through 2 years
MDedge Rheumatology
Dietary recommendations for inflammatory rheumatic diseases
MDedge Rheumatology
Patients are interrupting DMARD use well into the COVID-19 pandemic
MDedge Rheumatology
PsA: Secukinumab provides early and clinically meaningful improvements in patient-reported outcomes
MDedge Rheumatology
Psoriasis with concomitant psoriatic arthritis tied to an increased risk for endometriosis
MDedge Rheumatology
Predicting the risk for uveitis in juveniles with PsA
MDedge Rheumatology
Comorbidities account for an increased risk for VTE in PsA
MDedge Rheumatology
PsA: Time to clinically meaningful response shorter with tofacitinib vs. placebo
MDedge Rheumatology
Doppler signals and bone erosions at enthesis indicate more severe PsA
MDedge Rheumatology
MIC of PASDAS could serve as an additional tool to understand patients’ perspectives of PsA
MDedge Rheumatology